Buy Fertomid (Clomiphene Citrate 25mg / 50mg / 100mg) Online - Cipla Generic Clomiphene SERM Ovulation Induction
Fertomid (Clomiphene Citrate 25 mg / 50 mg / 100 mg) represents Cipla comprehensive generic clomiphene citrate line - providing the foundational Selective Estrogen Receptor Modulator (SERM) fertility therapy in three dose strengths with distinctively large pack sizes optimized for extended fertility protocols and bulk therapy requirements. Clomiphene citrate is the world foundational ovulation induction medication - originally FDA-approved in 1967 and continuously prescribed for over 55 years as first-line therapy for anovulatory infertility, PCOS ovulation induction, and comprehensive fertility support. Fertomid is manufactured by Cipla Limited - one of India largest pharmaceutical companies founded in 1935 with WHO-GMP certification, US FDA-inspected manufacturing facilities, and international regulatory approvals ensuring bioequivalent generic quality.
Clomiphene citrate works as a Selective Estrogen Receptor Modulator (SERM) through paradoxical anti-estrogenic action at the hypothalamus. First, clomiphene binds hypothalamic estrogen receptors as antagonist blocking normal estrogen negative feedback signaling. Second, this increases GnRH (gonadotropin-releasing hormone) pulsatility from the hypothalamus. Third, elevated GnRH stimulates pituitary FSH and LH release promoting ovarian follicular development. Fourth, mature follicles produce estradiol triggering the LH surge and ovulation approximately 5-10 days after last dose. Fifth, clomiphene provides predictable ovulation timing enabling timed intercourse or intrauterine insemination scheduling. Clinical evidence demonstrates 60-80 percent ovulation induction and 40-50 percent cumulative pregnancy rate over 6 cycles in appropriate candidates.
Fertomid serves comprehensive fertility indications including ovulatory dysfunction, polycystic ovary syndrome (PCOS), secondary amenorrhea, oligomenorrhea, and dysfunctional uterine bleeding. Common off-label uses include unexplained infertility with intrauterine insemination, oligospermia for male hypogonadism restoring testosterone through hypothalamic-pituitary stimulation, and luteal phase deficiency. Distinctive advantage of Fertomid is availability in three dose strengths (25/50/100 mg) enabling precise individualized titration across the full clinical range from sensitive patient starting doses through maximum escalation.
Fertomid is available in large pack sizes - 100, 200, and 300 tablets at each dose strength, providing distinctive bulk availability optimized for extended fertility treatment cycles, prolonged therapy protocols, or clinical practice bulk supply. This large-pack positioning distinguishes Fertomid within Cipla fertility portfolio for patients or practitioners requiring extended clomiphene supply. Contraindicated in pregnancy (Category X), liver disease, ovarian cysts, hormone-sensitive cancers, and pituitary tumors. Any visual disturbances require immediate discontinuation. Requires reproductive endocrinology supervision.
Free prescription
Discrete packaging
Have questions?
Quality Assurance
- Anovulatory Cycles: Menstrual cycles occurring without egg release requiring pharmacological ovulation induction for fertility;
- PCOS Ovulation Induction: Polycystic ovary syndrome is the most common cause of anovulatory infertility responsive to clomiphene;
- Polycystic Ovary Syndrome: Common endocrine disorder with anovulation hyperandrogenism and polycystic ovarian morphology;
- Stein Leventhal Syndrome: Historical name for PCOS - original clinical description of polycystic ovarian syndrome complex;
- Secondary Amenorrhea: Absence of menstruation for three or more months in previously menstruating reproductive age women;
- Oligomenorrhea: Infrequent menstruation with cycles longer than 35 days indicating ovulatory dysfunction and hormonal imbalance;
- Dysfunctional Uterine Bleeding: Abnormal uterine bleeding from anovulatory hormonal imbalance responding to cycle regulation;
- Hypothalamic Ovulation Disorders: Functional hypothalamic amenorrhea with adequate estrogen levels responds to clomiphene stimulation;
- Unexplained Infertility Off Label: Off-label empirical use with intrauterine insemination for couples without identifiable infertility cause;
- Male Oligospermia Off Label: Off-label use for male hypogonadism restoring testosterone through hypothalamic-pituitary axis stimulation;
- Superovulation for IUI: Multiple follicle development for intrauterine insemination protocols increasing pregnancy rates;
- Timed Intercourse Support: Predictable ovulation timing enables optimal timed intercourse for natural conception attempts;
- Luteal Phase Deficiency: Selected use for inadequate corpus luteum function producing progesterone deficiency after ovulation;
- First Line Fertility Therapy: Standard initial pharmacological approach before more intensive fertility interventions or IVF;
- Non Cancerous Galactorrhea: Selected use for hormonal galactorrhea after evaluation for pituitary and pathological causes;
- Chiari Frommel Syndrome: Post-partum amenorrhea-galactorrhea syndrome with prolonged lactation-related anovulation;
- Menstrual Cycle Regularization: Predictable ovulation restores regular menstrual cycles in anovulatory women through hormonal balance;
- Male Androgen Deficiency: Off-label secondary hypogonadism with low testosterone responding to hypothalamic-pituitary stimulation;
- Pituitary Gonadotropin Stimulation: Increases pituitary FSH and LH release stimulating ovarian follicular development and ovulation.
- Increases Pregnancy Chances: Restores ovulatory cycles enabling natural or assisted conception with 40-50 percent cumulative pregnancy rate over 6 cycles;
- Treats Polycystic Ovary Syndrome: First-line therapy for PCOS-related anovulation - most common cause of infertility responsive to clomiphene;
- Non Invasive Oral Medication Option: Simple oral tablet therapy without injections or surgical procedures - convenient first-line fertility approach;
- Three Strength Dosing Flexibility: 25/50/100 mg strengths enable precise dosing across full clinical range without tablet splitting or combining;
- Low Risk of Multiples: 8-10 percent twin risk substantially lower than injectable gonadotropins and IVF pregnancy therapies;
- Short Treatment Duration Per Cycle: Only 5 days per cycle simplifies treatment protocol and improves patient adherence significantly;
- Improves Luteal Phase Function: Successful ovulation produces natural corpus luteum progesterone supporting adequate luteal phase development;
- Normalizes Menstrual Cycle: Regular ovulatory cycles restored in majority of anovulatory patients providing hormonal regularization;
- Large Pack Size Convenience: 100 to 300 tablet packs support extended fertility protocols and reduce refill frequency requirements;
- Bulk Therapy Availability: Large packs optimized for extended treatment cycles and prolonged fertility protocol requirements;
- Predictable Ovulation Timing: Expected ovulation days 14-16 enables precise timed intercourse or IUI scheduling for conception;
- Cost Effective Fertility Therapy: Substantially more affordable than injectable gonadotropins for initial fertility treatment approach;
- Established Safety Profile: Over 55 years of continuous clinical use with well-established safety profile documentation;
- Dose Escalation Protocol: Progressive dose escalation from 50 to 100 to 150 mg enables individualized therapy optimization;
- Cipla Manufacturing Quality: WHO-GMP and US FDA-inspected manufacturing standards providing bioequivalent generic quality worldwide;
- 25mg for Sensitive Patients: 25 mg strength enables gentle starting dose for sensitive patients or half-dose protocols;
- Reversible Effects: Effects reverse after discontinuation without lasting hormonal disruption after therapy completion cycles;
- Foundational Fertility Medication: Over 55 years continuous clinical use as world reference ovulation induction therapy;
- Better Quality of Life: Successful pregnancy through effective fertility therapy dramatically improves quality of life for couples struggling with infertility.
Generic Fertomid (Clomifene IP 25 mg) Medication guide:
Fertomid (Clomiphene Citrate 25 mg / 50 mg / 100 mg) represents Cipla comprehensive generic clomiphene citrate line - providing the foundational Selective Estrogen Receptor Modulator (SERM) fertility therapy in three dose strengths with distinctively large pack sizes (100, 200, 300 tablets) optimized for extended fertility protocols and bulk therapy requirements. Clomiphene citrate is the world foundational ovulation induction medication - originally FDA-approved in 1967 and continuously prescribed for over 55 years as first-line therapy for anovulatory infertility, PCOS ovulation induction, and comprehensive fertility support. Fertomid is manufactured by Cipla Limited - one of India largest pharmaceutical companies founded in 1935 with WHO-GMP certification, US FDA-inspected manufacturing facilities, and international regulatory approvals ensuring bioequivalent generic quality. Approved for ovulatory dysfunction, PCOS ovulation induction, secondary amenorrhea, oligomenorrhea, and dysfunctional uterine bleeding. Common off-label uses include unexplained infertility with IUI, male oligospermia, and luteal phase support. This comprehensive medication guide covers SERM class pharmacology, hypothalamic-pituitary-ovarian axis mechanism, all approved indications, three-strength dosing advantage, comprehensive cycle protocols, CRITICAL visual disturbance and OHSS warnings, contraindications, drug interactions, and long-term fertility therapy considerations.
💊 Introduction to Fertomid
Fertomid is a prescription oral medication containing clomiphene citrate as its active ingredient in three dose strengths (25 mg, 50 mg, 100 mg) as oral tablets. Clomiphene citrate is a first-generation Selective Estrogen Receptor Modulator (SERM) - the foundational ovulation induction medication that established pharmacological ovulation therapy. Clomiphene citrate was originally developed and FDA-approved in 1967, establishing over 55 years of continuous clinical use as first-line therapy for anovulatory infertility worldwide.
Fertomid represents Cipla comprehensive generic clomiphene line - manufactured by Cipla Limited, one of India largest pharmaceutical companies founded in 1935 with global operations in over 80 countries. Cipla maintains WHO-GMP certification, US FDA-inspected manufacturing facilities, EU-GMP certification, and multiple international regulatory approvals ensuring bioequivalent generic Fertomid of consistent pharmaceutical quality supporting the same clinical effects expected from original brand clomiphene formulations.
Fertomid distinguishes itself within the clomiphene product category through three distinctive advantages. First, Fertomid offers three dose strengths (25 mg, 50 mg, and 100 mg) providing complete dosing flexibility across the full clinical range from sensitive patient starting doses through maximum escalation without tablet splitting or combining. Second, Fertomid provides large pack sizes (100, 200, and 300 tablets) at each strength - distinctively bulk positioning optimized for extended fertility protocols, prolonged therapy requirements, or clinical practice bulk supply. Third, Fertomid combines Cipla quality manufacturing with cost-effective pricing supporting long-term fertility treatment affordability.
Clomiphene citrate remains the foundational first-line fertility medication despite emergence of aromatase inhibitors (letrozole) as alternative first-line therapy in PCOS per PPCOS II 2014 trial. Clomiphene continues to serve as effective ovulation induction therapy for anovulatory infertility, PCOS management, and comprehensive fertility indications. The 60-80 percent ovulation induction rate and 40-50 percent cumulative pregnancy rate over 6 cycles in appropriate candidates demonstrate continued clinical value in modern reproductive endocrinology practice.
🏭 Cipla Manufacturer Heritage
Cipla Limited Credentials
Cipla Limited credentials:
- Founded 1935 in Mumbai India by Dr Khwaja Abdul Hamied - over 85 years pharmaceutical heritage
- Global operations in over 80 countries worldwide
- WHO-GMP certification - highest quality manufacturing standards
- US FDA-inspected facilities serving American regulatory market
- EU-GMP certification serving European market
- MHRA UK approval for United Kingdom distribution
- 50+ manufacturing facilities across multiple countries
- Third largest pharmaceutical company in India by revenue
- Comprehensive fertility and reproductive medicine portfolio
- Extensive gynecology and endocrinology product lines
- Cipla motto - Caring for Life - reflecting patient-centered mission
Manufacturing Quality Standards
Cipla produces Fertomid generic clomiphene citrate with rigorous quality control ensuring bioequivalent clomiphene content per tablet at each strength (25 mg, 50 mg, 100 mg), pharmaceutical-grade excipients, batch-to-batch consistency, stability testing for shelf-life reliability, and compliance with international pharmacopeia standards including Indian Pharmacopoeia (IP), United States Pharmacopoeia (USP), and British Pharmacopoeia (BP) requirements. The Cipla manufacturing infrastructure provides consistent quality supporting equivalent clinical effects to original brand clomiphene formulations for fertility therapy applications worldwide.
📜 Clomiphene Historical Development
Historical Timeline
| Year | Development Milestone |
|---|---|
| 1950s | Merrell Dow Pharmaceuticals research on triphenylethylene derivatives |
| 1961 | Clomiphene citrate first synthesized and characterized |
| 1967 | FDA approval of Clomid (original brand) by Merrell Dow for anovulatory infertility |
| 1970s-1980s | Establishment as global first-line ovulation induction therapy worldwide |
| 1980s-2000s | Generic clomiphene became widely available in international markets |
| 1990s | Cipla introduced Fertomid generic clomiphene brand for Indian and international markets |
| 2000s | Extensive research on clomiphene isomers - enclomiphene as pure agonist explored |
| 2007 | PPCOS I trial published - clomiphene remained first-line for PCOS |
| 2014 | PPCOS II trial (NEJM) - letrozole superior to clomiphene for PCOS (but clomiphene remains widely used) |
| Present Day | Over 55 years continuous clinical use - foundational ovulation induction medication worldwide |
Clomiphene Significance in Fertility Medicine
Clomiphene citrate introduction in 1967 revolutionized fertility medicine by providing the first oral pharmacological therapy for anovulatory infertility. Prior to clomiphene, women with anovulation had limited treatment options and often faced infertility without effective medical intervention. Clomiphene established the pharmacological approach to ovulation induction through hypothalamic-pituitary-ovarian axis modulation. Over 55 years of continuous clinical use has generated extensive safety and efficacy data supporting evidence-based prescribing. Despite emergence of newer alternatives (letrozole for PCOS per PPCOS II 2014), clomiphene remains widely prescribed foundational fertility therapy in international clinical practice.
🧬 Understanding SERMs Class
SERM Class Categories
SERM class categories:
- First-generation SERMs: Tamoxifen (breast cancer), toremifene, clomiphene (ovulation induction) - triphenylethylene derivatives
- Second-generation SERMs: Raloxifene - osteoporosis and breast cancer prevention
- Third-generation SERMs: Bazedoxifene, ospemifene, lasofoxifene - refined selectivity
- Fertility SERM specialty: Clomiphene provides mixed antagonist-agonist activity specifically for ovulation induction
Clomiphene Position Within SERM Class
Clomiphene occupies a distinctive position within the SERM class as the fertility-specific SERM providing tissue-selective estrogen receptor activity optimized for ovulation induction. Advantages include hypothalamic estrogen receptor antagonism releasing negative feedback on gonadotropin release, oral bioavailability enabling convenient tablet therapy, 5-day cycle dosing supporting timed intercourse or IUI protocols, well-established safety profile over 55 years, cost-effective compared to injectable gonadotropins, and predictable ovulation timing enabling reproductive planning. Clomiphene remains the reference first-line ovulation induction SERM despite alternatives now available.
🧪 Chemistry of Clomiphene
Chemical Structure
Clomiphene citrate has the chemical formula C26H28ClNO·C6H8O7 with molecular weight approximately 598.09 g/mol (as citrate salt). Chemically, clomiphene is a triphenylethylene derivative structurally related to tamoxifen. The clomiphene molecule contains one chlorine atom (distinguishing feature) and characteristic dimethylaminoethoxy side chain that provides estrogen receptor binding activity.
Isomer Composition
Clomiphene isomer composition:
- Enclomiphene (trans-isomer): Approximately 62 percent - pure estrogen receptor antagonist responsible for ovulation induction
- Zuclomiphene (cis-isomer): Approximately 38 percent - has mixed estrogen agonist activity and longer half-life
- Racemic mixture: Commercial clomiphene contains both isomers - each contributes different clinical effects
- Enclomiphene: Rapidly cleared - primary driver of therapeutic ovulation induction
- Zuclomiphene: Longer half-life (weeks) - may accumulate with repeated cycles and contribute to some side effects
Structural Features
- Triphenylethylene core structure - shared with tamoxifen
- Chlorine substituent - distinguishing feature vs tamoxifen
- Dimethylaminoethoxy side chain - critical for estrogen receptor binding
- Cis-trans isomeric mixture - unique among SERMs
- Highly protein bound to plasma proteins
- Hepatic metabolism with enterohepatic circulation
- Long tissue retention particularly zuclomiphene isomer
🔬 Mechanism of Action
Core Mechanism at Hypothalamic Level
Clomiphene mechanism step-by-step:
- Hypothalamic estrogen receptor binding: Clomiphene binds hypothalamic estrogen receptors as antagonist
- Blocks negative feedback: Prevents circulating estradiol from suppressing GnRH release
- Increased GnRH pulsatility: Hypothalamus perceives low estrogen state and increases GnRH pulse frequency
- Pituitary FSH and LH release: Elevated GnRH stimulates pituitary gonadotropin release
- Ovarian follicular development: FSH stimulates follicle growth in ovaries
- Estradiol production: Developing follicles produce estradiol from granulosa cells
- LH surge and ovulation: Rising estradiol triggers LH surge inducing ovulation
- Predictable ovulation timing: Ovulation occurs approximately 5-10 days after last clomiphene dose
Peripheral Anti-Estrogenic Effects
Clomiphene also exerts anti-estrogenic effects at peripheral tissues which can produce side effects and treatment limitations:
- Cervical mucus thinning: Reduces sperm penetration favorability - may need progesterone support
- Endometrial thinning: Reduces endometrial thickness potentially affecting implantation
- Vaginal dryness: Anti-estrogenic effect on vaginal tissue
- Visual disturbances: Retinal effects from estrogen receptor blockade
- Vasomotor effects: Hot flashes similar to menopausal symptoms
Fertility Therapeutic Effects
- Induces ovulation in 60-80 percent of appropriate anovulatory patients
- Achieves cumulative pregnancy rate of 40-50 percent over 6 cycles
- Provides predictable ovulation timing enabling timed intercourse or IUI
- Enables PCOS ovulation restoration as first-line therapy
- Supports luteal phase through natural corpus luteum progesterone production
- Can be used for superovulation supporting IUI protocols
- Effective for hypothalamic amenorrhea with adequate estrogen levels
🔬 Pharmacokinetic Profile
| Parameter | Value | Clinical Significance |
|---|---|---|
| Oral absorption | Well absorbed | Reliable oral therapy - not affected by food |
| Oral bioavailability | Good | Predictable clinical effects with oral dosing |
| Time to peak | 6-8 hours | Slow absorption timing |
| Enclomiphene half-life | Hours to days | Rapidly cleared - drives ovulation induction |
| Zuclomiphene half-life | Weeks | May accumulate with repeated cycles |
| Protein binding | Highly bound | Extensive plasma protein binding |
| Metabolism | Hepatic | Liver function affects clearance |
| Enterohepatic circulation | Significant | Prolongs zuclomiphene retention |
| Elimination | Fecal (primarily) | Approximately 50 percent excreted in feces |
| Ovulation timing | 5-10 days after last dose | Predictable ovulation for reproductive planning |
🧠 Understanding Ovulation Physiology
Normal Menstrual Cycle Ovulation
Normal ovulation physiology:
- Hypothalamus releases GnRH in pulsatile pattern
- Pituitary responds with FSH and LH release
- FSH stimulates ovarian follicular development
- Dominant follicle emerges around cycle day 8-10
- Estradiol rises from developing follicle
- LH surge triggers ovulation typically day 14
- Corpus luteum forms after ovulation producing progesterone
- Withdrawal bleeding if no conception occurs
Anovulatory Infertility Causes
- Polycystic Ovary Syndrome (PCOS): Most common cause of anovulation
- Hypothalamic amenorrhea: Functional causes affecting GnRH release
- Hyperprolactinemia: Elevated prolactin suppressing gonadotropins
- Thyroid dysfunction: Both hypo- and hyperthyroidism affect ovulation
- Premature ovarian insufficiency: Early ovarian failure
- Obesity: Affects hypothalamic-pituitary-ovarian axis function
- Excessive exercise or low weight: Functional hypothalamic amenorrhea
- Stress: Chronic stress affects hypothalamic function
🌸 Understanding Polycystic Ovary Syndrome (PCOS)
PCOS Overview
PCOS overview:
- Prevalence: Affects 8-13 percent of reproductive age women worldwide
- Most common cause of anovulatory infertility
- Rotterdam criteria diagnosis: 2 of 3 features required (oligomenorrhea/anovulation, hyperandrogenism, polycystic ovarian morphology)
- Anovulation mechanism: Elevated LH:FSH ratio, hyperandrogenism, insulin resistance
- Metabolic features: Insulin resistance, obesity, dyslipidemia common
- Long-term risks: Type 2 diabetes, cardiovascular disease, endometrial cancer
- Fertility impact: Anovulatory infertility is common presentation
Clomiphene Role in PCOS
Clomiphene citrate has been the traditional first-line ovulation induction therapy for PCOS for over 55 years. The 2014 PPCOS II trial demonstrated letrozole superiority to clomiphene for PCOS ovulation induction (27.5% vs 19.1% live birth rate) leading to letrozole becoming preferred first-line in many international guidelines. However, clomiphene remains widely used first-line therapy in many settings due to established efficacy, cost-effectiveness, familiarity, and continued good outcomes in appropriate PCOS patients.
🎯 FDA Approved Indications
- Ovulatory Dysfunction and Anovulatory Infertility
- Primary FDA-approved indication for female infertility due to ovulatory dysfunction or anovulation preventing conception. Requires adequate endogenous estrogen production. Standard dosing: 50 mg daily for 5 days starting cycle days 3-5.
- Polycystic Ovary Syndrome (PCOS) Ovulation Induction
- Traditional first-line ovulation induction therapy for PCOS. Effective for majority of PCOS patients although letrozole may be superior per PPCOS II 2014. Standard dosing: 50 mg daily x 5 days with escalation to 100-150 mg for non-responders.
- Secondary Amenorrhea
- Absence of menstruation for three or more months with adequate endogenous estrogen production. Diagnostic evaluation required to exclude other causes. Standard dosing: 50 mg daily x 5 days after negative pregnancy test.
- Oligomenorrhea
- Infrequent menstruation with cycles longer than 35 days indicating ovulatory dysfunction. Cyclic clomiphene therapy establishes predictable ovulation timing. Standard dosing: 50 mg daily x 5 days per cycle.
- Dysfunctional Uterine Bleeding
- Abnormal uterine bleeding from anovulatory hormonal imbalance responsive to cycle regulation. Requires diagnostic evaluation to exclude organic causes. Standard dosing per cycle.
- Stein-Leventhal Syndrome
- Historical clinical name for PCOS - original description of polycystic ovarian syndrome complex. Same clomiphene therapy applies as modern PCOS management.
🌸 Off-Label Uses
Common Off-Label Applications
Off-label uses of clomiphene citrate:
- Unexplained infertility with IUI: Empirical use with intrauterine insemination for couples without identifiable cause
- Superovulation for IUI: Multiple follicle development for enhanced pregnancy rates
- Male hypogonadism: Off-label for oligospermia through hypothalamic-pituitary-testicular axis stimulation
- Male secondary hypogonadism: Restoration of testosterone in men with functional hypothalamic causes
- Luteal phase deficiency: Selected use for inadequate corpus luteum function
- Chiari-Frommel syndrome: Post-partum amenorrhea-galactorrhea syndrome
- Non-cancerous galactorrhea: After evaluation for pituitary and pathological causes
- Anabolic steroid recovery: Off-label restoration of endogenous testosterone in athletes
Male Fertility Off-Label Use
Clomiphene citrate off-label use for male hypogonadism and oligospermia has grown substantially. Mechanism involves same hypothalamic estrogen receptor blockade increasing GnRH pulsatility, which stimulates pituitary LH and FSH release. LH stimulates testicular Leydig cell testosterone production. FSH stimulates spermatogenesis in Sertoli cells. Typical male dosing: 25 mg daily or every other day for months to years. Requires urology or endocrinology specialist supervision.
👤 Ideal Patient Selection
Fertomid most appropriate for:
- Women with anovulatory infertility with adequate endogenous estrogen
- PCOS patients requiring first-line ovulation induction (traditional approach)
- Women with hypothalamic amenorrhea with intact hypothalamic-pituitary function
- Women with oligomenorrhea requiring cycle regulation
- Women with secondary amenorrhea after diagnostic evaluation
- Couples undergoing intrauterine insemination protocols
- Couples with unexplained infertility considering ovulation induction
- Patients preferring cost-effective oral therapy vs injectable gonadotropins
- Patients requiring extended fertility treatment protocols benefiting from large pack sizes
- Practitioners requiring bulk clomiphene supply for fertility clinic use
- Patients accepting reproductive endocrinology monitoring during therapy
- Women without contraindications to SERM therapy
- Men with secondary hypogonadism (off-label use with urology guidance)
🚫 Contraindications
Absolute Contraindications
- Pregnancy - Pregnancy Category X - potential fetal harm
- Liver disease or hepatic dysfunction - metabolism impaired
- Ovarian cysts not due to PCOS - may exacerbate
- Uncontrolled thyroid or adrenal dysfunction - address underlying disorder first
- Pituitary tumor - contraindicated absolute
- Undiagnosed abnormal vaginal bleeding - requires diagnostic evaluation first
- Hormone-sensitive cancers (breast, endometrial, ovarian) - avoid stimulation
- Hypersensitivity to clomiphene or tablet excipients
- Endometriosis or uterine fibroids in severe form - may exacerbate
Visual Disturbances Warning
CRITICAL: Visual Disturbances Warning
Clomiphene can cause visual disturbances including blurred vision, spots, flashes, double vision, light sensitivity, and visual field defects. Any visual disturbances require IMMEDIATE DISCONTINUATION of clomiphene therapy.
Visual disturbance management:
- Discontinue clomiphene immediately if any visual symptoms develop
- Do not resume therapy after visual disturbances
- Some visual disturbances may become permanent if therapy continued
- Report any visual changes to prescriber immediately
- Do not drive if experiencing visual disturbances
- Consider ophthalmology consultation if symptoms persist
Ovarian Hyperstimulation Syndrome (OHSS) Warning
OHSS Warning:
Ovarian hyperstimulation syndrome is rare but serious complication of ovulation induction therapy. Signs include severe abdominal pain, distension, weight gain, breathing difficulty, and decreased urination.
OHSS Risk Management:
- Monitor ovarian response with ultrasound during therapy
- Discontinue at first sign of OHSS
- Immediate medical attention for severe symptoms
- PCOS patients at higher risk
- Consider lower starting doses in high-risk patients
Multiple Pregnancy Warning
Multiple Pregnancy Warning:
Clomiphene therapy is associated with 8-10 percent twin pregnancy rate and rare triplet or higher pregnancies. Higher rates than natural conception (approximately 1-2 percent). Counsel patients regarding multiple pregnancy possibility and associated risks.
💉 Three-Strength Dosing Advantage
Dose Strength Selection
| Strength | Primary Use | Patient Scenario |
|---|---|---|
| 25 mg | Sensitive patient starting dose | Small body size, prior sensitivity, half-dose protocols, or male fertility use |
| 50 mg | Standard starting dose | Most patients starting fertility therapy |
| 100 mg | First escalation dose | Non-responders to 50 mg starting dose |
| 150 mg (100 + 50) | Maximum standard dose | Non-responders to 100 mg escalation |
Dose Titration Protocol
Standard clomiphene dose titration:
- Cycle 1: 50 mg daily x 5 days starting cycle day 3-5
- Cycle 2 (if no ovulation): Escalate to 100 mg daily x 5 days
- Cycle 3 (if no ovulation): Escalate to 150 mg daily x 5 days maximum
- Non-responders at 150 mg: Consider alternative therapy (letrozole, gonadotropins, IVF)
- Response but no pregnancy: Continue effective dose for up to 6 cycles
- Successful ovulation: Continue for 3-6 cycles before considering IVF or alternative therapy
📆 Cycle Protocol Details
Standard Ovulation Induction Cycle
| Cycle Day | Activity |
|---|---|
| Day 1 | First day of menstruation (or withdrawal bleeding from progestin) |
| Day 3-5 | Start clomiphene (typical start day 5) |
| Day 5-9 | Continue clomiphene daily for 5 days |
| Day 10-14 | Follicular development phase - ultrasound monitoring optional |
| Day 14-16 | Expected ovulation - timed intercourse or IUI recommended |
| Day 21 | Mid-luteal progesterone to confirm ovulation |
| Day 28-35 | Pregnancy test if no menstruation - restart if negative |
Administration Guidelines
- Take tablets whole with water
- May be taken with or without food
- Take at approximately the same time each day during 5-day cycle
- Do not double dose if missed - discuss with prescriber
- Complete negative pregnancy test before starting each cycle
- Baseline ovarian ultrasound before starting therapy
- Monitor for visual disturbances - discontinue immediately if occur
- Track ovulation with basal body temperature or ovulation predictor kits
- Time intercourse or IUI to expected ovulation days 14-16
- Report severe abdominal pain suggesting OHSS immediately
- Maintain regular reproductive endocrinology follow-up
📊 Clinical Effectiveness Data
| Outcome | Response Data |
|---|---|
| Ovulation induction rate | 60-80 percent of appropriate patients |
| Cumulative pregnancy rate | 40-50 percent over 6 cycles |
| PCOS ovulation success | Effective in majority of PCOS patients |
| Time to conception | Most pregnancies within first 3 cycles |
| Twin pregnancy rate | Approximately 8-10 percent |
| Higher order multiples | Rare - less than 1 percent |
| Live birth rate per cycle | Variable by patient characteristics |
| Cost-effectiveness | Substantially more affordable than injectable gonadotropins |
⚠️ Side Effects
Common Side Effects
- Hot flashes: Approximately 10 percent - most common vasomotor symptom
- Ovarian enlargement: Approximately 14 percent - typically mild and resolves
- Breast tenderness: Common - typically mild
- Nausea and vomiting: Occasional
- Headache: Occasional
- Abdominal discomfort: Common - mild bloating and distension
- Mood changes: Common - emotional lability or depression
- Fatigue: Common
- Insomnia: Occasional
- Vaginal dryness: Common - anti-estrogenic effect
- Endometrial thinning: Common - anti-estrogenic effect
- Cervical mucus thinning: Common - may affect sperm penetration
- Weight gain: Occasional
- Dizziness: Occasional
Serious Adverse Events
Seek immediate medical attention for:
- Visual disturbances: Blurred vision, spots, flashes, double vision, light sensitivity - discontinue immediately
- Signs of OHSS: Severe abdominal pain, distension, weight gain, breathing difficulty
- Severe pelvic pain: Possible ovarian cyst rupture or torsion
- Severe allergic reactions
- Severe headache with neurological symptoms
- Signs of liver dysfunction: Jaundice, dark urine
- Severe depression or suicidal thoughts
- Signs of thromboembolism: Leg pain swelling, chest pain, shortness of breath
- Suspected pregnancy - discontinue immediately if pregnancy suspected
🔄 Drug Interactions
| Drug/Substance | Interaction |
|---|---|
| Estrogens (HRT) | Antagonize clomiphene effect - avoid combination |
| Oral contraceptives | Contraindicated combination (clomiphene for fertility) |
| Ospemifene, tamoxifen, other SERMs | Potential additive effects - avoid combination |
| Danazol | Antagonizes clomiphene effect |
| Human chorionic gonadotropin (hCG) | Often used adjunctively to trigger ovulation |
| Ganirelix, cetrorelix (GnRH antagonists) | May be used in IVF protocols with clomiphene |
| Metformin | Commonly combined for PCOS ovulation induction |
| Bromocriptine, cabergoline | Used for hyperprolactinemia before clomiphene therapy |
| Warfarin | Monitor INR - hormonal effects on coagulation |
🛡️ Special Populations
- Reproductive Age Women with Anovulatory Infertility
- Primary target population. Comprehensive fertility workup required including cycle history, hormonal evaluation, tubal patency assessment, and partner semen analysis before initiation.
- PCOS Patients
- Traditional first-line ovulation induction therapy. May be combined with metformin for insulin resistance. Consider letrozole as alternative per PPCOS II 2014 evidence. Weight management important before therapy.
- Hypothalamic Amenorrhea
- Effective if adequate endogenous estrogen present. Address underlying causes (stress, weight, exercise). May require estrogen supplementation before clomiphene if severely hypoestrogenic.
- Obese Patients
- Weight loss recommended before therapy for optimal response. May need higher doses or longer duration. Consider letrozole as more effective alternative in obese PCOS per PPCOS II data.
- Male Patients (Off-Label)
- Off-label use for secondary hypogonadism and oligospermia. Urology or endocrinology specialist supervision. Typical dosing 25 mg daily or every other day for months to years.
- Elderly Women
- Not indicated. Clomiphene not appropriate for postmenopausal women. Alternative therapies for postmenopausal indications.
- Pregnant Women
- Contraindicated. Pregnancy Category X. Confirm negative pregnancy test before each cycle. Discontinue immediately if pregnancy suspected.
- Depression History
- Monitor mood carefully during therapy. Mood changes common side effect. Consider mental health support during fertility treatment stress.
- Hepatic Impairment
- Contraindicated in significant liver disease. Metabolism impaired. Alternative fertility therapies needed.
- Endometriosis Patients
- May be used cautiously if symptoms mild and ovulation induction needed. Severe endometriosis may be contraindication due to potential stimulation.
- Multiple Pregnancy Risk Concern Patients
- Counsel regarding 8-10 percent twin risk. Consider single embryo transfer if IVF alternative preferred. Ultrasound monitoring recommended.
📦 Storage and Handling
- Store at room temperature 15-30°C (59-86°F)
- Protect from light and moisture
- Keep tablets in original packaging
- Keep out of reach of children and pets
- Do not use past expiration date
- Do not share medication with others
- Return unused medication to pharmacy for proper disposal
- Store in dry area - avoid humid bathrooms
👨⚕️ When to Contact Your Doctor
- Visual disturbances: blurred vision spots flashes double vision - discontinue immediately
- Signs of OHSS: severe abdominal pain distension weight gain
- Severe pelvic pain: possible ovarian cyst rupture or torsion
- Severe allergic reactions
- Severe headache with neurological symptoms
- Signs of liver dysfunction: jaundice dark urine
- Severe depression or suicidal thoughts
- Signs of thromboembolism: leg pain swelling chest pain shortness of breath
- Suspected pregnancy - discontinue immediately
- No menstruation 45 days after starting cycle
- Excessive ovarian enlargement
- Persistent hot flashes affecting quality of life
- No ovulation response after 3 escalating cycles
- Time for scheduled monitoring appointments
- Starting new medications potentially interacting
- Considering pregnancy tests and cycle planning
- Consultation about switching to alternative therapy
🌟 Key Takeaways
Essential points about Fertomid therapy:
- Fertomid is Cipla generic clomiphene citrate at three strengths (25/50/100 mg)
- Foundational SERM ovulation induction medication - FDA approved 1967
- Over 55 years continuous clinical use worldwide
- First-generation Selective Estrogen Receptor Modulator (SERM)
- Triphenylethylene chemistry - related to tamoxifen structurally
- Cis-trans isomer mixture - enclomiphene (active) plus zuclomiphene (accumulates)
- Works through hypothalamic estrogen receptor antagonism releasing negative feedback
- Increases GnRH pulsatility stimulating pituitary FSH and LH release
- Predictable ovulation approximately 5-10 days after last dose
- Standard dosing 50 mg daily x 5 days starting cycle days 3-5
- Escalate to 100-150 mg for non-responders through 3 cycles
- 60-80 percent ovulation induction rate in appropriate patients
- 40-50 percent cumulative pregnancy rate over 6 cycles
- 8-10 percent twin pregnancy rate
- Take at approximately same time each day during 5-day cycle
- May be taken with or without food
- Traditional first-line PCOS ovulation induction (letrozole superior per PPCOS II 2014)
- Off-label uses: unexplained infertility with IUI, male oligospermia
- Available in large pack sizes 100/200/300 for extended protocols
- CRITICAL: Visual disturbances require immediate discontinuation - may become permanent
- CRITICAL: OHSS risk - monitor for severe abdominal pain and distension
- Contraindicated in pregnancy (Category X), liver disease, ovarian cysts, hormone-sensitive cancers, pituitary tumor
- Cost-effective alternative to injectable gonadotropins for initial fertility therapy
- Requires reproductive endocrinology supervision
Important Medical Disclaimer: This medication guide provides general information about Fertomid (Cipla generic clomiphene citrate 25 mg / 50 mg / 100 mg tablets) and does not constitute individualized medical advice. Every patient situation is unique and requires evaluation by a reproductive endocrinologist, gynecologist, or qualified fertility specialist before starting ovulation induction therapy. Fertomid requires comprehensive fertility workup including cycle history documentation, hormonal evaluation (FSH, LH, estradiol, prolactin, TSH, androgens), tubal patency assessment (HSG or laparoscopy), pelvic ultrasound for baseline ovarian assessment, and partner semen analysis before initiation. Confirm negative pregnancy test before starting each cycle. CRITICAL SAFETY: Visual disturbances during clomiphene therapy require IMMEDIATE DISCONTINUATION - visual symptoms may become permanent if therapy continued. Report blurred vision, spots, flashes, double vision, light sensitivity, or any visual changes to prescriber immediately. Ovarian hyperstimulation syndrome (OHSS) is rare but serious complication requiring immediate medical attention for severe abdominal pain, distension, weight gain, or breathing difficulty. Multiple pregnancy rate is 8-10 percent for twins with rare higher-order multiples - counsel patients regarding multiple pregnancy risks. Contraindicated in pregnancy (Category X - potential fetal harm), liver disease, ovarian cysts not due to PCOS, uncontrolled thyroid or adrenal dysfunction, pituitary tumor, undiagnosed abnormal vaginal bleeding, and hormone-sensitive cancers. Ultrasound monitoring recommended during therapy especially in high-risk patients or higher doses. Mid-luteal progesterone testing confirms successful ovulation. Time intercourse or intrauterine insemination to expected ovulation days 14-16. Continue therapy up to 6 cycles at effective dose before considering alternative therapies (letrozole, injectable gonadotropins, IVF). PPCOS II 2014 trial demonstrated letrozole superior to clomiphene for PCOS ovulation induction (27.5% vs 19.1% live birth rate) - discuss best therapy option with reproductive endocrinologist. Report severe symptoms immediately. Regular reproductive endocrinology follow-up mandatory during therapy. If you experience concerning symptoms contact your healthcare provider promptly. The information provided here should complement but never replace direct professional medical guidance from your reproductive endocrinologist or fertility specialist.
Fertomid — Frequently Asked Questions
-
What is Fertomid?
Fertomid contains Clomifene Citrate, a medication used to treat infertility in women who do not ovulate, including helping women with PCOS conceive. -
How does Fertomid work?
Fertomid works by stimulating the release of hormones necessary for ovulation to occur, increasing the chance of pregnancy in women with ovulatory dysfunction. -
Who should take Fertomid?
Fertomid is prescribed to women who are infertile due to problems with ovulation, such as those with PCOS or other ovulatory disorders. -
How is Fertomid taken?
Typically, Fertomid is taken orally, starting on the fifth day of the menstrual cycle for five days, but the regimen may vary based on individual health conditions and doctor's recommendations. -
What are the possible side effects of Fertomid?
Common side effects include hot flashes, abdominal bloating, breast tenderness, and nausea. In rare cases, it may cause visual disturbances or ovarian hyperstimulation syndrome (OHSS). -
Can Fertomid cause multiple pregnancies?
Yes, Fertomid can increase the chance of twins due to the stimulation of multiple follicles, but the risk of higher-order multiples is relatively low. -
Is Fertomid effective for PCOS?
Yes, Fertomid is often effective in inducing ovulation in women with PCOS, thereby increasing their chances of conception.
See all Fertomid questions (32)
More Women's Health Medications
